PKAalpha/beta/gamma cat Blocking Peptide | PRKACA blocking peptide

PKA alpha/beta/gamma CAT Blocking Peptide

Cat. Num. AAA9619658

• Gene Names: PRKACA; PKACA; PPNAD4
• Applications: Blocking/Control
• Purity: The purity is >90%,tested by HPLC and MS.
• Synonyms: PKAalpha/beta/gamma cat; PKA alpha/beta/gamma CAT Blocking Peptide; cAMP dependent protein kinase alpha catalytic subunit; cAMP dependent protein kinase beta catalytic subunit; cAMP dependent protein kinase catalytic beta subunit isoform 4ab; cAMP dependent protein kinase catalytic subunit alpha; isoform 1; cAMP dependent protein kinase catalytic subunit beta; cAMP-dependent protein kinase catalytic subunit alpha; KAPCA_HUMAN; PKA C alpha; PKA C beta; PKA C-alpha; PKACA; PKACB; PPNAD4; PRKACA; PRKACAA; PRKACB; Protein kinase A catalytic subunit alpha; Protein kinase A catalytic subunit; Protein kinase A catalytic subunit beta; Protein kinase; cAMP dependent; catalytic; alpha; beta; cAMP-dependent protein kinase catalytic beta subunit isoform 4ab; cAMP-dependent protein kinase catalytic subunit beta; KAPCB_HUMAN; PKA C-beta; Prkacb; protein kinase A catalytic subunit beta; Protein kinase cAMP dependent catalytic beta; cAMP-dependent protein kinase catalytic subunit gamma; KAPCG_HUMAN; KAPG; PKA C gamma; PKA C-gamma; PKACg; PRKACG; Protein kinase cAMP dependent catalytic gamma; Serine (threonine) protein kinase; PRKACA blocking peptide

• Purity/Purification: The purity is >90%,tested by HPLC and MS.
• Form/Format: Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 10 mg/ml.

• Applicable Applications for PRKACA blocking peptide: Blocking/Control
• Notes: For phospho antibody, we provide phospho peptide (0.5mg) and non-phospho peptide (0.5mg)
• Preparation and Storage: Maintain refrigerated at 2-8 degree C for up to 6 months. For long term storage store at -20 degree C.

Related Product Information for PRKACA blocking peptide

Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. This mechanism is useful when non-specific binding is an issue, for example, in Western blotting (immunoblot) and immunohistochemistry (IHC). By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific; Specific binding will be absent from the western blot or immunostaining performed with the neutralized antibody.

NCBI and Uniprot Product Information

• NCBI GI #: 748585205
• NCBI GeneID: 5566
• NCBI Accession #: NP_001291278.1
• NCBI GenBank Nucleotide #: NM_001304349.1
• UniProt Accession #: P17612; Q32P54; Q9H2Y0; Q9NRB4; Q9NRH9
• Molecular Weight: 39,822 Da
• NCBI Official Full Name: cAMP-dependent protein kinase catalytic subunit alpha isoform 3
• NCBI Official Synonym Full Names: protein kinase cAMP-activated catalytic subunit alpha
• NCBI Official Symbol: PRKACA
• NCBI Official Synonym Symbols: PKACA; PPNAD4
• NCBI Protein Information: cAMP-dependent protein kinase catalytic subunit alpha
• UniProt Protein Name: cAMP-dependent protein kinase catalytic subunit alpha
• Protein Family: cAMP-dependent protein kinase
• UniProt Gene Name: PRKACA
• UniProt Synonym Gene Names: PKACA; PKA C-alpha
• UniProt Entry Name: KAPCA_HUMAN

NCBI Description

This gene encodes one of the catalytic subunits of protein kinase A, which exists as a tetrameric holoenzyme with two regulatory subunits and two catalytic subunits, in its inactive form. cAMP causes the dissociation of the inactive holoenzyme into a dimer of regulatory subunits bound to four cAMP and two free monomeric catalytic subunits. Four different regulatory subunits and three catalytic subunits have been identified in humans. cAMP-dependent phosphorylation of proteins by protein kinase A is important to many cellular processes, including differentiation, proliferation, and apoptosis. Constitutive activation of this gene caused either by somatic mutations, or genomic duplications of regions that include this gene, have been associated with hyperplasias and adenomas of the adrenal cortex and are linked to corticotropin-independent Cushing's syndrome. Alternative splicing results in multiple transcript variants encoding different isoforms. Tissue-specific isoforms that differ at the N-terminus have been described, and these isoforms may differ in the post-translational modifications that occur at the N-terminus of some isoforms. [provided by RefSeq, Jan 2015]